These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 15769897)

  • 1. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
    Choudhary C; Schwäble J; Brandts C; Tickenbrock L; Sargin B; Kindler T; Fischer T; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2005 Jul; 106(1):265-73. PubMed ID: 15769897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
    Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K
    Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
    Grundler R; Miething C; Thiede C; Peschel C; Duyster J
    Blood; 2005 Jun; 105(12):4792-9. PubMed ID: 15718420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
    Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H
    Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.
    Schwäble J; Choudhary C; Thiede C; Tickenbrock L; Sargin B; Steur C; Rehage M; Rudat A; Brandts C; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2005 Mar; 105(5):2107-14. PubMed ID: 15536149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
    Kindler T; Breitenbuecher F; Kasper S; Estey E; Giles F; Feldman E; Ehninger G; Schiller G; Klimek V; Nimer SD; Gratwohl A; Choudhary CR; Mueller-Tidow C; Serve H; Gschaidmeier H; Cohen PS; Huber C; Fischer T
    Blood; 2005 Jan; 105(1):335-40. PubMed ID: 15345593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
    Grundler R; Thiede C; Miething C; Steudel C; Peschel C; Duyster J
    Blood; 2003 Jul; 102(2):646-51. PubMed ID: 12663439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
    Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T
    J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLT3 mutations in acute myeloid leukemia cell lines.
    Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
    Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
    Bagrintseva K; Geisenhof S; Kern R; Eichenlaub S; Reindl C; Ellwart JW; Hiddemann W; Spiekermann K
    Blood; 2005 May; 105(9):3679-85. PubMed ID: 15626738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.
    Mizuki M; Schwable J; Steur C; Choudhary C; Agrawal S; Sargin B; Steffen B; Matsumura I; Kanakura Y; Böhmer FD; Müller-Tidow C; Berdel WE; Serve H
    Blood; 2003 Apr; 101(8):3164-73. PubMed ID: 12468433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.
    Tickenbrock L; Schwäble J; Wiedehage M; Steffen B; Sargin B; Choudhary C; Brandts C; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2005 May; 105(9):3699-706. PubMed ID: 15650056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
    Reindl C; Bagrintseva K; Vempati S; Schnittger S; Ellwart JW; Wenig K; Hopfner KP; Hiddemann W; Spiekermann K
    Blood; 2006 May; 107(9):3700-7. PubMed ID: 16410449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H
    Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.
    Leischner H; Albers C; Grundler R; Razumovskaya E; Spiekermann K; Bohlander S; Rönnstrand L; Götze K; Peschel C; Duyster J
    Blood; 2012 Apr; 119(17):4026-33. PubMed ID: 22411868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLT3-TKD mutation in childhood acute myeloid leukemia.
    Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH
    Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.
    Scheijen B; Ngo HT; Kang H; Griffin JD
    Oncogene; 2004 Apr; 23(19):3338-49. PubMed ID: 14981546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.
    Kiyoi H; Ohno R; Ueda R; Saito H; Naoe T
    Oncogene; 2002 Apr; 21(16):2555-63. PubMed ID: 11971190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.